Polydeoxyribonucleotide Injectables Market growing at a CAGR of 16.2% from 2025 to 2033

The global polydeoxyribonucleotide injectables market size was estimated at USD 211.37 million in 2024 and is projected to reach USD 803.55 million by 2033, growing at a CAGR of 16.2% from 2025 to 2033. This growth is driven by increasing awareness of aesthetic treatments, technological advancements, and a move towards minimally invasive therapies.

Combination PDRN injectables are quickly gaining widespread acceptance because they can single-handedly address multiple skin problems. To illustrate, the debut of VAMP by Prollenium represents a new milestone in skin revitalization. The product pairs PDRN with a nutrient cocktail of vitamins, amino acids, and minerals to deliver skin firmness, hydration, and quality at a whole new level. VAMP sets out to breathe new life into the skin tone, shrink pore sizes, and wrinkle-free, and give the already compromised skin a chance to rejuvenate; therefore, it is on the cutting edge of aesthetic dermatology as its name suggests. According to a research article published by Science Direct, hyaluronic acid-polydeoxyribonucleotide (HA-PDRN) cross-linked hydrogels are a very efficient means of skin regeneration. The hydrogels made by the covalent bonding of carboxyl groups of Hyaluronic Acid to amino groups of PDRN show enhanced biocompatibility and more collagen production than those made solely from Hyaluronic Acid. These studies indicate the immense possibilities of developing more stable and effective injectable treatments by combining PDRN and HA.

Market Concentration & Characteristics

The PDRN injectables market demonstrates a moderate level of industry concentration, with key players investing in innovative formulations and advanced technologies. Cosmetic PDRN injections, such as Rejuran, are widely adopted across South Korea and parts of Europe. For example, in countries like India, companies such as Dermat India and Cipla are emerging as notable manufacturers-Dermat India focusing on high-quality, compliant PDRN products through advanced R&D, and Cipla expanding its portfolio with regenerative therapeutic solutions. These developments highlight the market’s steady global expansion driven by innovation and rising demand for non-surgical aesthetic treatments.

The market is going through significant changes, new formulations, and manufacturing processes being the main reasons for this change. The manufacturers have already implemented leading-edge biotechnological procedures in India, such as using recombinant DNA technology to produce PDRN of high purity and quality without contamination. Such a formulation as polydeoxyribonucleotides combined with vitamins, amino acids, and minerals, like Prollenium’s VAMP, makes skin rejuvenation progression more remarkable. All these technological breakthroughs signify a new period in aesthetic dermatology, where scientific accuracy and customer-specific delivery methods result in better regenerative and anti-aging effects.

Polydeoxyribonucleotide Injectables Market Report Scope